Publication | Closed Access

Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study

UrologyGenitourinary CancerMedicinePathologyMuscle-invasive Bladder CancerPure-01 StudyNeoadjuvant PembrolizumabCancer TreatmentOncologyCancer GrowthTumor Microenvironment